Skip to content

Kura Oncology KURA Common Stock

Common Stock at other companies

Amgen logo
AmgenAMGN
2.8B0.0%
Exelixis logo
ExelixisEXEL
400M0.0%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$9K0.0%
AbbVie logo
AbbVieABBV
$18M0.0%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$8K+14.3%
Nuvation Bio logo
Nuvation BioNUVB
$1.43B+3.5%

Other financials

Income statement

See full
Revenue$18.3M+29.5%
Gross profit$18.0M
Operating income-$78.8M-21.8%
Net income-$73.3M-27.7%
EPS (diluted)-$0.83-25.8%

Balance sheet

See full
Cash & equivalents$39.1M-23.8%
Total debt$24.3M+25.4%
Total equity$107.9M-70.4%
Total assets$652.6M-12.3%

Cash flow

See full
Operating cash flow-$85.9M-19.4%
CapEx$128.0K-56.2%
Free cash flow-$86.0M-19.1%

Valuation

See full
Market cap$919.7M+81.6%
Enterprise value$904.89M+90.7%
P/S12.8×+3.5×

Profitability

See full
Operating margin-443.5%+103pp
Net margin-411.2%+125pp
FCF margin130.6%+74.1pp

Returns & leverage

See full
Return on equity-124.7%-252pp
Debt / equity0.2×+0.2×
Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kura Oncology's common stock?
Kura Oncology (KURA) reported common stock of $9K in Q1 2026.
How has Kura Oncology's common stock changed year-over-year?
Kura Oncology's common stock increased by 12.5% year-over-year, from $8K to $9K.
What is the long-term trend for Kura Oncology's common stock?
Over 5 years (2020 to 2025), Kura Oncology's common stock has grown at a 5.2% compound annual growth rate (CAGR), from $7K to $9K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).